561 filings
Page 4 of 29
6-K
bhx g2cbt
17 May 21
Current report (foreign)
8:15am
6-K
55z1mu740xyc71r2m
13 May 21
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
8:15am
6-K
cya na2qj4
6 May 21
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
11:23am
6-K
smhmg0 ei
6 May 21
Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
11:17am
6-K
d71hdeky5m e98newgvp
6 May 21
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
11:12am
6-K
hols96xo
5 May 21
Condensed Interim Consolidated Financial Statements
12:00am
6-K
1oyb3r
9 Apr 21
Annual Meeting of Shareholders
5:23pm
6-K
ogjf7t4g s8
22 Mar 21
Current report (foreign)
4:32pm
6-K
qnekk0f5izvd8
19 Mar 21
Current report (foreign)
12:00am
6-K
1ul6w
16 Mar 21
Current report (foreign)
1:15pm
6-K
6q00xtqhwhc
11 Mar 21
Announces the Initiation of Its Preclinical Program for the Potential
8:30am
6-K
0e5qzw8m ea4cio
9 Mar 21
Current report (foreign)
7:00am
6-K
5bh46ieg4zaibiawlmzh
18 Feb 21
Current report (foreign)
4:05pm
6-K
0n3lksnpqh
2 Feb 21
Current report (foreign)
7:40am
6-K
hbiwxw6kdcelimjrdn1
28 Jan 21
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
4:05pm
6-K
10fn j6n7h
26 Jan 21
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
5:30pm
6-K
dber893gzpx5m4
7 Dec 20
Current report (foreign)
8:15am
6-K
auqz i3iiq7bye5
16 Nov 20
Current report (foreign)
8:15am
6-K
45r2 vb0p59tf9b
5 Nov 20
Condensed Interim Consolidated Financial Statements
4:32pm
6-K
8dz73
7 Oct 20
Current report (foreign)
9:11am